Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

Medixon 500mg powder for injection

Ferron Par Pharmaceuticals

Ingredients in every 8 ml

Methylprednisolone 500 mg

Each package contains

1 vial of 500 mg

Dosage form

Powder for injection

Dosage formPowder for injection

Flavour

None

W.H.O. classification

H02A
H02A

A.T.C. Level 1

Anatomical Main group

H - Systemic hormonal preparations; excluding sex hormones and insulins
H02A

A.T.C. Level 2

Therapeutic subgroup

H02 - Corticosteroids for Systemic Use
H02A

A.T.C. Level 3

Pharmacological subgroup

H02A - Corticosteroids for Systemic Use; Plain

Available in

Indonesia

Warnings

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

NOT RECOMMENDEDThis item should not be used while operating heavy machinery.

Pregnancy

CAUTIONThis item may not be safe for use during pregnancy. Use with caution and after consultation with your doctor.

Lactation

CAUTIONThis item may not be safe for use during lactation. Use with caution and after consultation with your doctor.

Indication

– Endocrine disorders
– Allergic disorders
– Gangguan disorders
– Dermatologic disorders
– Gastrointestinal disorders
– Hematologic disorders
– Hepatic diseases
– Nonrheumatoid inflammation
– Neoplastic diseases
– Nephrotic syndrome
– Neurologic diseases
– Neurotrauma
– Ophthalmic disorders
– Pericarditis
– Nasal polyps
– Respiratory disorders.

Dosage

UP TO 18 YEARS
— Adrenocortical insufficiency:
Intramuscular, 0.18 mg (base) per kg of body weight or 3.33 mg (base) per square meter of body surface area daily (in three divided doses) every third day

— Acute spinal cord injury treatment:
Intravenous, 30 mg (base) per kg of body weight administered over a 15 minutes, followed after 45 minutes by a continuous infusion of 5.4 mg per kg of body weight per hour, for 23 hours.

— Adjunctive treatment in patients with Pneumocystis carinii pneumonia associated with AIDS:
Children up to 14 years of age: dosage has not been established.
Children 14 years of age or older: see Adults and adolescents dose.

18 YEARS OLD AND ABOVE
IM/IV 10 –40 mg (base), repeated as needed

High dose (pulse therapy): IV, 30 mg (base) per kg of body weight administered over at least 30 minutes. This dose may be repeated every 4-6 hours for 48 hours.

— Acute exacerbations of multiple sclerosis:
Intramuscular or intravenous, 160 mg (base) daily for 1 week, followed by 64 mg (base) every other day for 1 month

— Acute spinal cord injury treatment:
Intravenous, 30 mg (base) per kg of body weight administered over 15 minutes, followed after 45 minutes by a continuous infusion of 5.4mg per kg of body weight per hour, for 23 hours.

— Adjunctive treatment in patients with Pneumocystis carinii pneumonia associated with AIDS:
Intravenous,
– 30 mg (base) twice daily on days one through five,
– 30 mg once daily on days six through ten, and
– 15 mg once daily on days eleven through twenty one.

DIRECTIONS FOR USE
IM or IV injection:
Reconstitute powder by adding solvent (containing benzyl alcohol 0.9%), mix homogeneously. Direct intravenously can be given at least 1 minute or can be given by intravenously infusion in dextrose 5%, NaCl 0.9% or dextrose 5% in NaCl 0.9% for at least 30 minutes. The solution is stable physically and chemically for 48 hours.